Sanofi took another step in its oncology pipeline rebuild with the first clinical evidence that a cornerstone program of its oncology pipeline — precision engineered IL-2 therapy THOR-717 -- may be...

Asher Bio emerged from stealth Tuesday with a $55 million series A led by Third Rock and a platform to improve the safety and efficacy of cytokine therapies for cancer.  Boxer Capital, Invus and seed...

Insitro Inc. said existing investor Canada Pension Plan Investment Board led its new $400 million series C round, which builds on a $143 million series B closed in May 2020. Also backing the machine learning-guided drug...

Rubius believes an early readout from its lead program in solid tumors represents a validating event for its RED platform, but after seeing a 13% overall response rate in a clinical study, the company is...

Following a Phase II miss for imsidolimab to treat palmoplantar pustulosis, AnaptysBio will look ahead to five other indications for the IL-36R antagonist. The company plans to bring imsidolimab (ANB019) into Phase III testing mid-year for generalized...

AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for Boehringer Ingelheim GmbH, which has spesolimab (BI...

As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than Arvinas’ single-arm,...

Novavax Inc. (NASDAQ:NVAX) said in its 4Q20 earnings report that it is discussing COVID-19 vaccine NVX-CoV2373 with FDA and may submit a request for emergency use authorization of candidate next quarter. The biotech announced on...